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Abstract 
Background: Normal and cancerous tissues have distinct auto-fluorescence properties because of differences in 
their biophysical and biochemical agents. Scientific evidences related to diagnostic fluorescence imaging for detec-
tion of oral precancerous and cancerous lesions are very limited.
Objectives: The aim of this study was to find out potential relationships between serum, salivary and tissue proto-
porphyrin IX ( PX) levels in subjects with or without oral precancerous  and cancerous lesions. Also, to find out 
diagnostic value of fluorescence imaging (VELscope® system, LED Dental Inc., White Rock, B.C.)  and salivary 
protoporphyrin IX (PX) in oral precancerous and cancerous lesions. Furthermore this study attempts to find out 
diagnostic value of the combination of approaches of fluorescence imaging and salivary protoporphyrin for detec-
tion of oral precancerous and cancerous lesions.  
Material and Methods: The study sample comprised 3 test groups, with biopsy confirmed precancerous (leukopla-
kia and lichen planus) and cancerous lesions (squamous cell carcinoma) and one control group of 25 healthy indi-
viduals. To find out sensitivity and specificity, another 100 patients presenting for routine dental care were selected 
and clinical examinations were followed by fluorescence imaging and normal photography, which were finally 
confirmed by biopsy. The clinical and histopathogical examinations were done in conjunction with photography 
of the oral cavity using digital camera and fluorescence imaging. Serum, tissue and salivary protoporphyrin (PX) 
levels were measured.
Results: Using fluorescence imaging, oral cancerous and precancerous lesions showed deep purple to deep brown 
and dark green colour respectively, while normal tissues showed pale green colour in contrast. The PX levels in 
serum, salivary and tissues were significantly higher in precancerous and cancerous lesions as compared to normal 
healthy tissues. Salivary and serum PX levels were highly correlated in all groups. The sensitivity and specificity 
to the discrimination of precancerous and cancerous lesions from the healthy tissues were higher by combination 
approaches of salivary protoporphyrin X and VELscope® system as compared individual approach.
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Introduction
Head and neck cancers constitute a large proportion of 
cancers in India accounting for 23% of all cancers in 
males and 6% in females (1). The vast majority of the-
se cancers are related to consumption of tobacco, alco-
hol, poor hygiene, diet and viral infections (2,3). Early 
detection and diagnosis of premalignant and malignant 
oral mucosal lesions have the potential to significantly 
reduce patient morbidity and mortality. Unfortunately, 
the clinical appearance of these lesions can often be so 
understated that these may remain unnoticed or ignored 
by patients or dentists. Furthermore, the lesions can be 
difficult to clinically differentiate from more common 
benign tissue changes, such as those associated with 
infectious or inflammatory sources or post-surgical al-
terations (4-6). A non-invasive and reliable adjunctive 
tool that directs clinicians towards sites suspicious for 
pre-malignancy could lead to significant advancements 
in early detection and diagnosis of oral precancerous and 
cancerous lesions. 
In recent years, visual tools for helping in the diagnosis 
of oral cancer have made important advancements by 
adding luminous detection systems (chemoluminescen-
ce and tissue fluorescence techniques) for improving de-
tection and increasing the capacity to identify potentially 
malignant lesions (6-12). The VELscope® system (Vi-
sually Enhanced Lesion Scope; LED Dental Inc., White 
Rock, B.C.) is a simple handheld device detecting the 
loss of fluorescence in visible and non-visible high-risk 
oral lesions by applying direct fluorescence. The loss of 
fluorescence reflects a complex mixture of alterations to 
the intrinsic tissue distribution of fluorophores (7-13). 
Hence, early biochemical changes are detected by their 
more evident appearance, permitting early detection of 
pathological lesions (14). In the past, few studies have 
evaluated this system (11-12). Reported sensitivity va-
lues ranged from 97% to 98% and specificity from 94% 
to 100% (8-19). Preliminary results were promising, 
yet information regarding the ability of the VELscope 
to identify premalignant regions within Class II (inno-
cuous) lesions or to reveal lesions otherwise visually 
undetectable is limited. 
The autofluorescence lifetimes of normal, precancerous, 
and cancerous tissues are different because of varying 
biochemical changes, enabling characterization of the 
various lesions. Protoporphyrin IX (PX), an important 
Conclusions: Combination approach of salivary protoporphyrin X and VELscope® system are more sensitive and 
specific to discriminate precancerous and cancerous lesions from the healthy tissues as compared to individual appro-
ach. Further studies are required on large samples of oral precancerous and cancerous lesions to test sensitivity and 
specificity and thus validate the clinical applicability of fluorescence imaging in (pre)cancerous diagnostics. 
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chemical of heme synthesis, is one kind of natural fluo-
rophores in human cells (13). One of the rate limiting 
steps in the heme biosynthesis pathway is the conver-
sion of protoporphyrin IX (i.e. the photosensitizer) to 
heme, which is controlled by a rate-limiting enzyme, 
ferrochelatase (FC), through adding a ferrous iron to PX 
(14). Because of a lack of ferrochelatase, cancerous cells 
may accumulate more PX, presenting significantly lon-
ger fluorescence lifetime than that of normal cells. So, 
till date no study was published on ferrochelatase and 
protoporphyrin IX levels in oral precancerous and can-
cerous lesions and their relation to VELscope imaging. 
Hence, the aim of this study was to find out the relation-
ship between fluorescence imaging and protoporphyrin 
IX levels in tissues, serum and saliva of oral precance-
rous and cancerous patients. This study tried to validate 
a simple non-invasive approach used for the diagnosis of 
occult oral diseases.
Material and Methods 
-Subjects: Twenty five squamous cell carcinoma (SCC), 
30 leukloplakia (OLU, age 56-75 years; M:F; 15:15) and 
25 lichen planus patients ( aged;  54-76 years; M:F;13:12) 
with biopsy-confirmed and 25 normal healthy ( age 54-75 
years, M:F; 13:12) were recruited, after taking informed 
consent based on the definition of oral cancer and pre-
cancerous lesions by the World Health Organization (9). 
Ethical approval was taken from centre under JBR society 
(Ethical approval number JBR#1238).  An additional 100 
patients (aged; 45-75 years, M:F; 52:48) for testing sen-
sitivity and specificity presenting for routine dental care 
were selected. Patients with history of chemotherapy, ra-
diotherapy, oncological surgery, obesity, systemic disea-
ses, bronchial asthma, drug allergies, alcohol abuse and 
smoking were excluded from the study.
-Clinical and Laboratory investigations: All subjects un-
derwent comprehensive clinical examinations, followed 
by fluorescence imaging and white light photography. 
Positive imaging areas were referred for confirmation 
by scalpel biopsy and further histopathological exami-
nations. Photographs of oral cavity tissues were taken 
with a digital camera and VELscope (LED Med. Inc., 
White Rock, BC0 (8-12).
-VELscope examination: Room lights were dimmed 
and the oral cavity was re-examined using the VELs-
cope. Visual fluorescence retention (VFR) and visual 
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fluorescence loss (VFL) were assessed and mapped on a 
data collection sheet. VFL was defined as mucosal sites 
which showed a reduction in the normal pale green auto 
fluorescence (appeared dark) when compared to adjacent 
tissues and as an anatomic control compared to tissues 
on the contra lateral side. The examiner’s clinical im-
pression/clinical diagnosis of areas exhibiting VFL were 
recorded. VFL was considered a positive VELscope fin-
ding and, therefore, necessitated biopsy. The VELscope 
images and white digital images were compared. 
-Oral biopsy and tissue preparation: Oral biopsies of le-
sions as well as normal healthy tissues were taken for 
analysis of PX by one of the oral surgeon. Two-mm 
punch biopsies were trimmed to remove a large part, fro-
zen in liquid nitrogen, and homogenized at 2,000 r.p.m. 
with the Microdismembrator U (Merck KgaA, Darms-
tadt, Germany ) for 2 min. Chloroform: methanol (2:1 
vol/vol, Merck KgaA, Darmstadt, Germany) mixture 
was used as an extraction medium. Mixtures were cen-
trifuged for 15 min at 15,000 r.p.m., and the supernatant 
was collected for further analysis. A second extraction 
cycle was performed by adding the same amount of 
chloroform: methanol (2:1 vol/vol) mixture to the pellet. 
This mixture was vortexed for at least 5 min until a new 
suspension was formed and centrifuged for 15 min at 
15,000 r.p.m. Subsequently, the supernatant was collec-
ted and added to the supernatant from the first extrac-
tion cycle. The PpIX extraction procedure was identical 
to the procedure used by previous study (15). All these 
steps were performed in a dark laboratory environment 
taking ultimate care to prevent exposure of the speci-
mens to light. 
-Serum and salivary protoporphyrin analysis: Approxi-
mately 5 ml of blood sample was drawn under aseptic 
precautions and centrifuged for 5 min to obtain serum 
which was stored at –65° C in sterile vials. During the 
examination paraffin wax stimulated whole saliva was 
collected, and samples were stored at -20°C until analy-
sis. Serum and salivary protoporphyrin levels were mea-
sured fluorometrically as in a previous study (16). 
-Statistical analysis: Kruskal-Wallis H-test with Bon-
ferroni correction was used for comparing salivary and 
serum PX in controls and patients. Sensitivity and spe-
cificity and the corresponding 95% IC were calculated 
for VELscope and salivary PX as well as combination 
of VELscope and salivary PX by biopsy examination. 
Furthermore, mean salivary and serum PX of the groups 
were correlated by using Pearson s correlation test. 
Results
Patient’s demographic data are shown in table 1. The 
oral cancerous and precancerous lesions showed deep 
purple to deep brown and dark green colour changes 
respectively while normal showed pale green. All pre-
cancerous and cancerous exhibited some degree of VFL. 
The protoporphyrin X levels in serum, salivary and tis-
sue were significantly higher in precancerous and cance-
rous patients as compared to normal healthy individuals 
(P=0.01), furthermore, the levels were also significantly 
higher in cancerous as compared to precancerous pa-
tients (Table 2, P=0.05). Salivary and serum PX levels 
were highly correlated (R²= 0.72) in all groups. Salivary 
and tissues PX were moderate correlated (R²=0.68) and 
high correlation was also found in serum and tissue PX 
(R²=0.75) in all groups. Sensitivity and specificity values 
were also calculated to evaluate the validity of VELs-
cope examination and salivary PX in oral precancerous 
and cancerous lesions. The cutoff value of salivary PX 
levels 0.39, 0.26, 0.24, 0.11 mg/ml for squamous cell 
carcinoma, oral leukoplakia, oral lichen planus and nor-
mal healthy individuals were taken. 
The sensitivity and specificity to the discrimination of 
precancerous and cancerous lesions & condition from 
the healthy tissues were higher by combination appro-
aches of salivary protoporphyrin X and VELscope® 
system compared to individual approach (Table 3). 
Table 1. Demographic characteristics of patients and controls.
Variables Oral leukoplakia Oral lichen planus Squamous cell 
carcinoma
Controls
Gender 30  ( M: F; 15:15) 25 ( M:F; 10:15) 25 ( M:F; 13:12) 50 ( M:F; 25:25)
Sites 30  buccal mucosa 15 buccal mucosa, 10 
retromolar areas
25 buccal mucosa
Smokers  (cigarettes /daily) 17[4.7] 18[6.5] 17[5.8] 16[4.6]
Alcoholic status 
(g of alcohol/daily)
523[234] 546[198] 565[341] 546[345]
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Table 2. Mean and Standard deviation (SD) Tissue, serum and salivary protoporphyrin  IX levels in oral precancerous and cancerous (squamous 
cell carcinoma, oral leukoplakia, oral lichen planus) and normal healthy subjects. 
Subjects Serum protoporphyrin 
IX levels  (mg/l)
Salivary protoporphyrin 
IX levels (mg/l)
Tissue protoporphyrin IX levels 
(pmol per mL)
Squamous cell carcinoma 2.58 ( 1.59)* 0.45 (0.32)a 35.3 (4.8)b
Oral leukoplakia 1.99 (1.25)* 0.32 (0.27)a 28.5 (7.9)b
Oral lichen planus 1.77 (1.35)* 0.31(0.22)a 20.8(6.8)b
Normal Healthy 0.76 (0.46) 0.12 (0.18) 10.2 (7.8)
*p<0.005 compared with normal healthy. 
ap<0.005 compared with normal healthy.
bp<0.005 compared  with normal healthy.
Value in % Squamous cell  carcinoma Oral leukoplakia Oral lichen planus Normal healthy
SP VEL SPVEL SP VEL SPVEL SP VEL SPVEL SP VEL SPVEL
Sensitivity 71 67 80 68 63 79 69 60 80 68 78 79
Specificity 70 62 79 65 53 77 65 61 78 68 74 79
Table 3. Sensitivity and specificity of salivary protoporphyrin ( SP), VELscope ( VEL),  and combination of salivary protoporphyrin and  VEL-
scope ( SPVEL) in oral precancerous and cancerous lesions.
Discussion
The endogenous fluorophores that are most important 
for optical screening and diagnosis of precancerous and 
cancerous lesions are those exciting in the spectrum 
from visible blue (400–450 nm) to UV-A (315–400 nm) 
with properties spectroscopically correlated to diseased 
tissues. The concept behind tissue auto-florescence is 
change in the structure, metabolism of the epithelium, 
as well as change of the subepithelial stroma which al-
ters their interaction with light (11-18). Endogenous por-
phyrins have been controversially discussed in literature 
concerning their tumor-localizing properties (19,20). A 
most common theory is that, the red fluorescence is a 
product of microbial porphyrin synthesis and therefore 
its distribution is limited to the necrotic surface of ne-
crotic tumors (20). The oral cancerous lesions appeared 
deep purple to deep brown and precancerous appeared 
dark green while normal showed pale green colour chan-
ges. It might be due to higher accumulation of PPIX and 
a decrease of green auto fluorescence within the pre-
cancerous and cancerous lesions. This seems to occur 
because of a relative lack of ferro-chelatase, an enzy-
me required to incorporate chelated iron into PP IX to 
form the heme molecule (11,18). Higher concentration 
of PIX in serum, tissues and saliva was found in cance-
rous and pre-cancerous conditions as compared to nor-
mal healthy. Tissue, salivary and serum PX levels were 
highly correlated in all groups. Also, salivary and tissue 
PX were highly correlated. Therefore, salivary testing, a 
non-invasive alternative to serum and tissues testing can 
be considered as an effective modality for diagnosis and 
for prognosis prediction of various diseases such as oral 
cancer and pre-cancerous lesions, as well as for monito-
ring the patient’s post therapy status. 
The VELscope is a portable clinical diagnostic tool per-
mitting the direct visualization of the oral cavity and is 
sold for use in the screening of oral cancer. Oral can-
cerous and precancerous lesions show deep purple to 
deep brown and dark green colour changes respectively 
while normal shows pale green. VELscope achieved a 
sensitivity of 62.8% and specificity of 62.2% in discri-
minating clinically evident oral pre-cancerous and can-
cerous lesions from normal tissue which is lower than 
previous reports (16,17,18,21-23). The tonality for in-
terpretation purposes is straightforward: pale green for 
healthy tissues and dark green, brown or black (loss of 
fluorescence) for a pathological situation. The VELs-
cope is intended to be used by a dentist or health-care 
provider as an adjunct to traditional oral examination by 
incandescent light to enhance the visualization of oral 
mucosal abnormalities that may not be apparent or visi-
ble to the naked eye, such as oral cancer or premalignant 
dysplasia (11,17-23). VELscope is intended to be used 
by a surgeon to help identify diseased tissue around a 
clinically apparent lesion and thus aid in determining the 
appropriate margin for surgical excision. The sensitivity 
and specificity to the discrimination of precancerous and 
cancerous lesions from the healthy tissues were higher 
by combination approaches of salivary protoporphyrin 
X and VELscope® system as compared to individual 
approach. Further studies are required to further inves-
tigate large samples of oral precancerous and cancerous 
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lesions to test sensitivity and specificity and thus valida-
te the clinical applicability of combination approach of 
fluorescence imaging and salivary biomarkers in (pre)
cancerous diagnostics. 
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